NCT06867107View on ClinicalTrials.gov

A Long-term Follow-up Study for Participants That Completed the SAT-3247-CL-101 Study

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

DRUG

SAT-3247

AAK1 inhibitor

Trial Locations (1)

Unknown

St. Vincent Hospital, Melbourne

All Listed Sponsors

lead

Satellos Bioscience, Inc.

INDUSTRY